open access

Vol 86, No 6 (2015)
ARTICLES
Get Citation

Expression of caveolin-1 in peritumoral stroma is associated with histological grade in ovarian serous tumors

Sevil Sayhan, Gulden Diniz, Tugba Karadeniz, Duygu Ayaz, Dudu Solakoglu Kahraman, Mehmet Gokcu, Hulya Tosun Yildirim
DOI: 10.17772/gp/2398
·
Ginekol Pol 2015;86(6).

open access

Vol 86, No 6 (2015)
ARTICLES

Abstract

Background: Previous studies have demonstrated that Caveolin-1 (Cav-1) can ambiguously behave as tumor suppressor or tumor promoter in different neoplasms, depending on cancer type. Some findings have also revealed that cell proliferation, migration and invasion were attenuated by the knockdown of Caveolin-1 expressions. However, the functional and prognostic significance of Caveolin-1 in most tumors remains to be fully elucidated. Objectives: The aim of the study was to investigate a possible association between tissue Caveolin-1 expression and the clinicopathologic features of ovarian serous tumors. Material and methods: Caveolin-1 expression was studied in a total of 82 formalin-fixed, paraffin-embedded specimens of ovarian serous tumors and its association with different clinicopathologic parameters was evaluated. Results: The study included 36 (43.9%) benign, 12 (14.6%) borderline and 34 (41.5%) malignant serous tumors. Mean patient age was 43.9±14.4 years (17-72 years). Statistical analysis revealed that if the tumor becomes more aggressive and invasive, it losses the stromal Caveolin-1 expression (p=0.001). Also, parallel changes between stromal and perivascular Caveolin-1 expressions were observed. Conclusions: Our findings demonstrated a link between Caveolin-1 expression and the aggressiveness of ovarian cancer. Therefore, it seems safe to suggest that Cav-1 may act as a differential diagnostic biomarker in ovarian serous tumors.

Abstract

Background: Previous studies have demonstrated that Caveolin-1 (Cav-1) can ambiguously behave as tumor suppressor or tumor promoter in different neoplasms, depending on cancer type. Some findings have also revealed that cell proliferation, migration and invasion were attenuated by the knockdown of Caveolin-1 expressions. However, the functional and prognostic significance of Caveolin-1 in most tumors remains to be fully elucidated. Objectives: The aim of the study was to investigate a possible association between tissue Caveolin-1 expression and the clinicopathologic features of ovarian serous tumors. Material and methods: Caveolin-1 expression was studied in a total of 82 formalin-fixed, paraffin-embedded specimens of ovarian serous tumors and its association with different clinicopathologic parameters was evaluated. Results: The study included 36 (43.9%) benign, 12 (14.6%) borderline and 34 (41.5%) malignant serous tumors. Mean patient age was 43.9±14.4 years (17-72 years). Statistical analysis revealed that if the tumor becomes more aggressive and invasive, it losses the stromal Caveolin-1 expression (p=0.001). Also, parallel changes between stromal and perivascular Caveolin-1 expressions were observed. Conclusions: Our findings demonstrated a link between Caveolin-1 expression and the aggressiveness of ovarian cancer. Therefore, it seems safe to suggest that Cav-1 may act as a differential diagnostic biomarker in ovarian serous tumors.
Get Citation

Keywords

Caveolin-1 / serous tumors / ovary /

About this article
Title

Expression of caveolin-1 in peritumoral stroma is associated with histological grade in ovarian serous tumors

Journal

Ginekologia Polska

Issue

Vol 86, No 6 (2015)

DOI

10.17772/gp/2398

Bibliographic record

Ginekol Pol 2015;86(6).

Keywords

Caveolin-1 / serous tumors / ovary /

Authors

Sevil Sayhan
Gulden Diniz
Tugba Karadeniz
Duygu Ayaz
Dudu Solakoglu Kahraman
Mehmet Gokcu
Hulya Tosun Yildirim

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl